A comparison of the effectiveness anti-platelet drugs in patients undergoing coronary artery by-pass: A clinical trial

Platelets play a key role in cardiovascular disease both in the pathogenesis of atherosclerosis and in the development of acute thrombotic events. Their importance in vascular disease is indirectly confirmed by the benefit of antiplatelet agents in these disorders. Antiplatelet agents are the cornerstone of treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Clopidogrel, has proved considerable success at reducing thrombotic complications of ACS and/or PCI compared to aspirin alone. Despite clopidogrel's ability to effectively prevent myocardial infarction (MI), stroke or death in patients with ACS and those undergoing PCI, it has limitations that compromise its clinical utility delayed onset of action, modest platelet inhibition and variability in patients' responses. Anti-platelet therapy with clopidogrel has be come the standard treatment for the reduction of ischemic events in patients with coronary artery disease (CAD) with stenting, espe cially those undergoing drug-eluting stent (DES) implantation. Anticoagulant effect of clopidogrel is of utmost importance in coronary artery disease, especially in prevention of coronary stent thrombosis. Recently, a new local brand of clopidogrel has been launched, as Osvix (by OSVEH Company, Tehran, Iran). This study was conducted with the aim to compare two locally prepared clopidogrel brands (Osvix & Plavix), in terms of the effect on inhibition of platelet aggregation in patients with coronary artery disease